Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression

References

• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439–444.
   PubMedGoogle Scholar
• Gilbert LA Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell 2010;143:355–366.
   PubMed Web of Science ®Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519–2526.
   PubMed Web of Science ®Google Scholar
• Podar K, Chauha D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10–24.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114:3625–3628.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30–36.
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907–4916.
   PubMed Web of Science ®Google Scholar
• Anderson KC. Targeted therapy of multiple myeloma based upon tumor microenvironmental interactions. Exp Hematol 2007;35:155–162.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585–598.
   PubMed Web of Science ®Google Scholar
• Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
   PubMed Web of Science ®Google Scholar
• Chang H, Li D, Zhuang L, et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004;45:965–969.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor in the pathophysiology of human multiple myeloma:therapeutic applications. Oncogene 2001;20:4519–4527.
   PubMed Web of Science ®Google Scholar
• Gatt ME, Zhao JJ, Ebert MS, et al. MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 2010 Oct 20. [Epub ahead of print]
   PubMedGoogle Scholar
• Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669–6680.
   PubMed Web of Science ®Google Scholar
• Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591–599.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva N, et al. MY-3002: a phase 3 study comparing bortezomib melphalan prednisone (VMP) with melphalan prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007;110(Suppl. 1): Abstract 73.
   Google Scholar
• Roorda BD, ter Elst A, Kamps WA, de Bont ES. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009;69:187–198.
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383–1395.
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006;103:19478–19483.
   PubMed Web of Science ®Google Scholar
• Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 2009;15:249–254.
   PubMed Web of Science ®Google Scholar
• Hua Z, Lv Q, Ye W, et al. miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116.
   PubMed Web of Science ®Google Scholar
• Corthals SL, Jongen-Lavrencic M, de Knegt Y, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010;34:677–681.
   PubMed Web of Science ®Google Scholar
• Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008;118:3714–3724.
   PubMed Web of Science ®Google Scholar